Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response

Siamoglou, Stavroula; Boers, Ruben; Koromina, Maria; Boers, Joachim; Tsironi, Anna; Chatzilygeroudi, Theodora; Lazaris, Vasileios; Verigou, Evgenia; Kourakli, Alexandra; van IJcken, Wilfred F. J.; Gribnau, Joost; Symeonidis, Argiris; Patrinos, George P.

doi:10.1186/s40246-023-00483-7

Human Genomics

Table 1 Differentially methylated regions (DMRs) with fold change values above 3.5 after comparing extensive against partial responders to HMA treatment

From: Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response

Chromosome	Start	End	Fold Change	Genomic loci description	Genomic annotation
chr18	50,268,329	50,269,073	9.36	CpG-island	CpG22007
chr18	50,268,329	50,269,073	9.36	postTSS1KB-TES	MBD1
chr10	132,798,382	132,798,411	8.08	CpG-island	CpG6383
chr16	89,191,731	89,192,381	5.98	CpG-island	CpG18255
chr16	89,191,731	89,192,381	5.98	postTSS1KB-TES	CDH15
chr7	158,425,441	158,425,470	5.79	CpG-island	CpG47995
chr7	158,425,441	158,425,470	5.79	postTSS1KB-TES	PTPRN2
chr9	113,059,365	113,090,635	5.33	CpG-island	CpG51787
chr1	3,073,145	3,073,734	4.72	CpG-island	CpG275
chr1	3,073,145	3,073,734	4.72	postTSS1KB-TES	PRDM16
chr20	33,667,004	33,668,579	4.64	CpG-island	CpG30320
chr20	33,667,004	33,668,579	4.64	TSS	ACTL10
chr20	33,667,004	33,668,579	4.64	postTSS1KB-TES	NECAB3
chr20	33,667,004	33,668,579	4,64	postTSS1KB-TES	ACTL10
chr1	143,653,686	143,654,706	4,46	CpG-island	CpG2556
chr1	143,653,686	143,654,706	4,46	CpG-island	CpG2557
chr19	35,994,135	35,994,360	4,22	CpG-island	CpG24507
chr19	35,994,135	35,994,360	4,22	TSS	SDHAF1
chr19	7,862,503	7,862,711	4,08	CpG-island	CpG23476
chr19	7,862,503	7,862,711	4,08	postTSS1KB-TES	EVI5L
chr1	228,276,077	228,276,359	3,92	CpG-island	CpG4054
chr1	228,276,077	228,276,359	3,92	TSS	RP5-1139B12.3
chr1	228,276,077	228,276,359	3,92	postTSS1KB-TES	OBSCN
chr5	191,246	191,885	3,80	CpG-island	CpG38456
chr5	191,246	191,885	3,80	TSS	LRRC14B
chr1	2,122,668	2,122,914	3,65	CpG-island	CpG192
chr1	2,122,668	2,122,914	3,65	postTSS1KB-TES	PRKCZ
chr19	3,980,801	3,980,830	3,65	postTSS1KB-TES	EEF2
chr10	59,881,067	59,883,404	3,63	CpG-island	CpG5231
chr10	59,881,067	59,883,404	3,63	postTSS1KB-TES	CCDC6
chr19	58,356,134	58,356,892	3,59	CpG-island	CpG25795
chr19	58,356,134	58,356,892	3,59	postTSS1KB-TES	CTD-2619J13.8
chr19	58,356,134	58,356,892	3,59	postTSS1KB-TES	ZNF497

Chromosome loci of the DMRs, fold change and genomic annotation with regard to the identified DMRs. TSS Transcription Start Site, TES Transcription End Site; postTSS1KB-TES, indicates the region starting at 1 Kb after the TSS until the TES thus corresponding to the gene body without promoter region

Back to article page

ISSN: 1479-7364

Contact us

General enquiries: journalsubmissions@springernature.com